Deciphera Pharmaceuticals Announces Retirement of Daniel L. Flynn, Ph.D., and Appointment of Dashyant Dhanak, Ph.D., as Executive Vice President and Chief Scientific Officer

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that the Company’s Founder, Executive Vice President, and Chief Scientific Officer, Daniel L. Flynn, Ph.D., will retire effective September 5, 2023 and will transition to a role as Senior Advisor to the Company. Dashyant Dhanak, Ph.D., has been appointed Executive Vice President and Chief Scientific Officer effective September 5, 2023.

Dr. Dhanak brings over 30 years of experience in pharmaceutical research and development and joins Deciphera from Incyte Corporation where he was Executive Vice President and Chief Scientific Officer.

“On behalf of all my colleagues, I want to thank Dan for his vision to found Deciphera two decades ago as a company dedicated to improving the lives of people with cancer. It has been an honor to work alongside such a trailblazing researcher whose innovations in drug discovery now benefit thousands of cancer patients around the world and have the potential to continue making an impact for years to come thanks to our rich clinical and pre-clinical pipeline developed from the research engine that Dan created,” said Steve Hoerter, President and Chief Executive Officer of Deciphera Pharmaceuticals. “We are excited to build on our track record of innovation in drug discovery with the announcement that Dash Dhanak is joining Deciphera as our new Chief Scientific Officer. In addition to broad experience in drug discovery and development, Dash is a proven leader with a track record of advancing innovative oncology agents to the clinic. I look forward to working with Dash to continue to build a strong pipeline of novel therapies at Deciphera.”

“I am unbelievably proud of Deciphera’s progress and accomplishments in the years since I founded the company. We have grown from a small research team into a fully-integrated biotechnology company with capabilities from research to international commercialization, anchored as always by a culture that seeks to drive innovation to help patients as our first priority. Together, we have improved the quality of life for many cancer patients around the world,” said Dr. Flynn. “I am confident that the Company’s discovery and early-stage programs are in excellent hands with Dash, and under his leadership, I know Deciphera will develop additional important new medicines for the treatment of cancer.”